行情

GBT

GBT

全球血液疗法
NASDAQ

实时行情|Nasdaq Last Sale

53.03
-0.11
-0.21%
已收盘, 17:07 09/17 EDT
开盘
52.98
昨收
53.14
最高
53.36
最低
51.42
成交量
60.90万
成交额
--
52周最高
64.94
52周最低
30.15
市值
31.83亿
市盈率(TTM)
-14.5695
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GBT 新闻

  • 日本社交巨头Line推出加密交易平台Bitmax
  • TechWeb.44分钟前
  • WeWork拟今年完成IPO:估值缩水八成,创始人表悔意
  • 澎湃新闻.49分钟前
  • 财经天下:IMF新掌门将面临哪些挑战?
  • 中国新闻网.54分钟前
  • 13家大型投行前瞻:美联储料降息25个基点 微调声明
  • 汇通网.58分钟前

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

GBT 简况

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
展开

Webull提供Global Blood Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。